Synergistic Effects of PD-1 Blockade Combined with Neoadjuvant Chemoradiotherapy in Muscle-Invasive Bladder Cancer: A Retrospective Single-Centre Cohort Study

This record contains de-identified clinical, treatment, pathological and safety data from a retrospective cohort of 59 patients with cT2–T4aN0M0 muscle-invasive urothelial carcinoma of the bladder treated at the First Affiliated Hospital of Soochow University between January 2021 and December 2024. Twenty-seven patients received gemcitabine/cisplatin-based neoadjuvant chemoradiotherapy (NACRT) alone, whereas thirty-two received identical NACRT plus a PD-1 inhibitor (toripalimab, n = 18; tislelizumab, n = 14). Intensity-modulated pelvic irradiation delivered 45 Gy in 25 fractions with a 10 Gy bladder boost; systemic therapy was administered every 21 days for at least three cycles. Key variables include baseline demographics (age, sex, BMI, smoking, comorbidities, ECOG status), clinical staging, treatment details (drug dosages, radiation parameters, antibody type), post-cystectomy pathology (ypT, ypN), and treatment-related adverse events graded by CTCAE v5.0. Primary endpoints are pathological down-staging (≤ ypT1N0) and pathological complete response (ypT0N0); secondary endpoint is incidence and severity of acute toxicity. The dataset supports comparative analyses of pathological response rates and safety profiles between NACRT alone and NACRT plus PD-1 blockade, and may facilitate future meta-analyses or translational studies investigating tri-modality therapy in bladder cancer.